The announcement of an exclusive licensing agreement for PEDMARQSI, a potentially significant product, with Norgine represents a major strategic move for Fennec Pharmaceuticals. This partnership not only opens up new markets for PEDMARQSI in Europe, Australia, and New Zealand but also likely enhances Fennec's revenue prospects and market positioning in these regions. The positive market reaction reflects investor optimism about the deal's potential to drive growth and profitability.